Approved production of Zhifei biological typhoid Vi polysaccharide vaccine

According to the information on June 18 on the website of the State Food and Drug Administration (CFDA), the production approval of typhoid Vi polysaccharide vaccine declared by Beijing green bamboo bio pharmaceutical, a wholly-owned subsidiary of Zhifei bio, has been issued, with the national drug approval number of s20140007 At present, a number of biological Institutes under the group have approval documents for the vaccine, and the market is relatively mature Typhoid Vi polysaccharide vaccine is mainly used to prevent typhoid caused by Salmonella typhi It is suitable for children and adults over 2 years old Zhifei said the product will further enrich the company's product line and enhance its profitability It is expected that the vaccine will take more than nine months to go on the market, which has no impact on this year's performance Chi Fei also warned that typhoid fever is closely related to the sanitary conditions With the improvement of public health conditions, typhoid fever incidence rate has been stable or declining Typhoid Vaccine's future market space is relatively limited, and has little effect on the company's performance.